Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects

被引:12
|
作者
Ooi, Esther M. M. [1 ]
Janus, Edward D. [2 ]
Grant, Susan J. [3 ]
Sinclair, Lucia M. T. [3 ]
Barrett, P. Hugh R. [1 ]
机构
[1] Univ Western Australia, Royal Perth Hosp, Sch Med & Pharmacol, Metab Res Ctr, Perth, WA 6009, Australia
[2] Univ Melbourne, Western Hosp, Dept Med, Footscray, Vic, Australia
[3] Princess Margaret Hosp, Christchurch 2, New Zealand
基金
英国医学研究理事会;
关键词
apoE2/E2; genotype; kinetics; Type III hyperlipidemia; INTERMEDIATE DENSITY LIPOPROTEINS; RECEPTOR-BINDING ACTIVITY; III HYPERLIPOPROTEINEMIA; FAMILIAL DYSBETALIPOPROTEINEMIA; B METABOLISM; ARTERY-DISEASE; PLASMA; VARIANT; ATHEROSCLEROSIS; HUMANS;
D O I
10.1194/jlr.M004705
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of apolipoprotein (apo) E genotype on apoB-100 metabolism was examined in three normolipidemic apoE2/E2, five type III hyperlipidemic apoE2/E2, and five hyperlipidemic apoE3/E2 subjects using simultaneous administration of I-131-VLDL and I-125-LDL, and multi-compartmental modeling. Compared with normolipidemic apoE2/E2 subjects, type III hyperlipidemic E2/E2 subjects had increased plasma and VLDL cholesterol, plasma and VLDL triglycerides, and VLDL and intermediate density lipoprotein (IDL) apoB concentrations (P < 0.05). These abnormalities were chiefly a consequence of decreased VLDL and IDL apoB fractional catabolic rate (FCR). Compared with hyperlipidemic E3/E2 subjects, type III hyperlipidemic E2/E2 subjects had increased IDL apoB concentration and decreased conversion of IDL to LDL particles (P < 0.05). In a pooled analysis, VLDL cholesterol was positively associated with VLDL and IDL apoB concentrations and the proportion of VLDL apoB in the slowly turning over VLDL pool, and was negatively associated with VLDL apoB FCR after adjusting for subject group. VLDL triglyceride was positively associated with VLDL apoB concentration and VLDL and IDL apoB production rates after adjusting for subject group. A defective apoE contributes to altered lipoprotein metabolism but is not sufficient to cause overt hyperlipidemia. Additional genetic mutations and environmental factors, including insulin resistance and obesity, may contribute to the development of type III hyperlipidemia. Ooi, E. M. M., E. D. Janus, S. J. Grant, L. M. T. Sinclair, and P. H. R. Barrett. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects. J. Lipid Res. 2010. 51: 2413-2421.
引用
收藏
页码:2413 / 2421
页数:9
相关论文
共 50 条
  • [31] Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects
    Cohn, JS
    Tremblay, M
    Amiot, M
    Bouthillier, D
    Roy, M
    Genest, J
    Davignon, J
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (01) : 149 - 159
  • [32] APOLIPOPROTEIN E-ENRICHED LIPOPROTEIN SUBCLASSES IN NORMOLIPIDEMIC SUBJECTS
    GIBSON, JC
    RUBINSTEIN, A
    BUKBERG, PR
    BROWN, WV
    JOURNAL OF LIPID RESEARCH, 1983, 24 (07) : 886 - 898
  • [33] Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects
    Marcoux, C
    Tremblay, M
    Fredenrich, A
    Jacques, H
    Krimbou, L
    Nakajima, K
    Davignon, J
    Cohn, JS
    ATHEROSCLEROSIS, 1998, 139 (01) : 161 - 171
  • [34] STRUCTURAL DOMAINS OF APOLIPOPROTEIN(A) AND ITS INTERACTION WITH APOLIPOPROTEIN B-100 IN THE LIPOPROTEIN(A) PARTICLE
    HUBY, T
    DOUCET, C
    DIEPLINGER, H
    CHAPMAN, J
    THILLET, J
    BIOCHEMISTRY, 1994, 33 (11) : 3335 - 3341
  • [35] IMPACT OF AGE ON THE METABOLISM OF VLDL, IDL, AND LDL APOLIPOPROTEIN B-100 IN MEN
    MILLAR, JS
    LICHTENSTEIN, AH
    CUCHEL, M
    DOLNIKOWSKI, GG
    HACHEY, DL
    COHN, JS
    SCHAEFER, EJ
    JOURNAL OF LIPID RESEARCH, 1995, 36 (06) : 1155 - 1167
  • [36] APOLIPOPROTEIN E METABOLISM IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT
    RALL, CJN
    HOEG, JM
    LAW, SW
    MONGE, JC
    GREGG, RE
    ZECH, LA
    BREWER, HB
    CIRCULATION, 1987, 76 (04) : 119 - 119
  • [37] Pharmacological profiling of apolipoprotein B-100 and microsomal triglyceride transfer protein antisense inhibitors in hyperlipidemic mice
    Lemonidis, KM
    Whipple, CP
    Graham, MJ
    Crooke, RM
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E60 - E61
  • [38] VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100
    Zulewski, H
    Ninnis, R
    Miserez, AR
    Baumstark, MW
    Keller, U
    JOURNAL OF LIPID RESEARCH, 1998, 39 (02) : 380 - 387
  • [39] DIFFERENCES IN THE PHENOTYPIC CHARACTERISTICS OF SUBJECTS WITH FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 AND FAMILIAL HYPERCHOLESTEROLEMIA
    MISEREZ, AR
    KELLER, U
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (10) : 1719 - 1729
  • [40] Inhibition of the procoagulant activity of thromboplastin by apolipoprotein B-100
    Adam, JM
    Ettelaie, C
    James, NJ
    Bruckdorfer, KR
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 187 - 187